Hiroshi Kagamu - Comprehensive Cancer CenterInternational Medical Center, Saitama Medical University

基本信息

浏览量：57

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 245 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Clinical Significance of Post‑progression Survival after Chemoradiotherapy on Overall Survival in Limited‑disease Small Cell Lung Cancer

Ayako Shiono,Hisao Imai, Satoshi Endo, Shohei Okazaki,Takanori Abe,Atsuto Mouri,Kyoichi Kaira,Ken Masubuchi,Kunihiko Kobayashi,Koichi Minato,Shingo Kato,Hiroshi Kagamu

Molecular and clinical oncologyno. 6 (2025): 58-58

引用0浏览0WOS引用

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study

Yuhei Kurata,Atsuto Mouri,Hisao Imai, Satoshi Endo, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura,Ayako Shiono,Ou Yamaguchi,Junichi Nakagawa,Kyoichi Kaira,Kunihiko Kobayashi,Hiroshi Kagamu

Medicinano. 6 (2025): 994

引用0浏览0引用

A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients with Nonsmall Lung Cancer Treated with Nivolumab Plus Ipilimumab

Atsuto Mouri,Hisao Imai, Satoshi Endo,Junichi Nakagawa, Kasumi Tsukamoto, Yuhei Kurata,Ou Yamaguchi, Kenji Masaki, Kosuke Hashimoto,Ayako Shiono, Yu Miura,Kunihiko Kobayashi,Kyoichi Kaira,Hiroshi Kagamu

Cancer medicineno. 8 (2025): e70741-e70741

引用0浏览0WOS引用

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab Treatment in Elderly Patients (aged ≥ 75 Years) with Non-Small Cell Lung Cancer

Satoshi Endo,Hisao Imai,Atsuto Mouri,Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto,Yu Miura,Ayako Shiono,Ou Yamaguchi,Junichi Nakagawa,Kyoichi Kaira,Kunihiko Kobayashi,Hiroshi Kagamu

Journal of Cancer Research and Clinical Oncologyno. 1 (2025): 1-12

引用0浏览0WOS引用

Efficacy and Safety of Amrubicin Monotherapy after Chemoradiotherapy in Patients with Relapsed Limited Disease Small-cell Lung Cancer

Akira Matsukida,Hisao Imai,Ayako Shiono,Yasuhiro Ryuno, Kosuke Hashimoto,Y U Miura, Satoshi Endo,Shohei Okazaki, O U Yamaguchi,Atsuto Mouri,Takanori Abe,Kyoichi Kaira,Kunihiko Kobayashi,Shingo Kato,Hiroshi Kagamu

Anticancer research（2025）

引用0浏览0WOS引用

A Multicenter, Prospective, Observational Study of Nivolumab Readministration for Advanced Gastric Cancer (NIVO RETURNS)

Hiroyuki Kodama,Yukiya Narita,Michio Nakamura,Masanobu Takahashi,Takuro Mizukami,Takayuki Ando,Seiichiro Mitani,Azusa Komori,Ayumu Hosokawa,Toshikazu Moriwaki,Keiji Sugiyama,Masataka Taguri,Shunichiro Orihara,Hiroshi Kagamu,Toshifumi Yamaguchi,Hiroki Nishikawa,Kei Muro

Future oncology (London, England)no. 14 (2025): 1753-1759

引用0浏览0WOS引用

Metabolic Tumor Volume on 18F-FDG Uptake As a Negative Predictor after Ipilimumab Plus Nivolumab in Advanced Non-Small Cell Lung Cancer

Kosuke Hashimoto,Kyoichi Kaira,Atsuto Mouri,Ayako Shiono, Yu Miura,Ou Yamaguchi,Hisao Imai,Hiroshi Kagamu,Ichiei Kuji

Translational lung cancer researchno. 4 (2025): 1242-1253

引用0浏览0WOS引用

[Prediction of Anti-Tumor Immunity-Significance of a Novel Th1-Like CD4+ T-Cell Cluster]

Hiroshi Kagamu

Gan to kagaku ryoho Cancer & chemotherapyno. 5 (2025): 377-382

引用0浏览0WOS引用

A Retrospective Evaluation of Therapeutic Efficacy and Safety of Chemoradiotherapy in Older Patients (aged ≥ 75 Years) with Limited-Disease Small Cell Lung Cancer: Insights from Two Institutions and Review of the Literature

Ayako Shiono,Hisao Imai, Satoshi Endo,Kazuki Katayama,Hideaki Sato,Kosuke Hashimoto,Yu Miura,Shohei Okazaki,Takanori Abe,Atsuto Mouri,Kyoichi Kaira,Ken Masubuchi,Kunihiko Kobayashi,Koichi Minato,Shingo Kato,Hiroshi Kagamu

RADIOLOGY AND ONCOLOGY（2024）

引用0浏览0WOS引用

Membranous Nephropathy As a Paraneoplastic Syndrome in Cancer of Unknown Primary

Kyoichi Kaira,Hiroaki Amano,Hisao Imai,Hirokazu Okada,Hiroshi Kagamu

In Vivono. 3 (2024): 1503-1508

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn